Bevacizumab/capecitabine/irinotecan/oxaliplatinChronic myeloid leukaemia: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1575卷 / 1期

关键词：

D O I：

10.1007/s40278-015-1749-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：42 / 42

相关论文

共 50 条

[21] Bevacizumab/capecitabine/oxaliplatinNausea and diarrhoea: case report
Reactions Weekly, 2013, 1455 (1) : 9 - 9
[22] Bevacizumab/irinotecan/temozolomideHaematological toxicity: case report
Reactions Weekly, 2018, 1725 (1) : 59 - 59
[23] Bevacizumab/irinotecan/temozolomideAneurysmal subarachnoid haemorrhages: case report
Reactions Weekly, 2014, 1518 (1) : 46 - 46
[24] Bevacizumab/capecitabine/irinotecanHand and foot syndrome: case report
Reactions Weekly, 2017, 1660 (1) : 82 - 82
[25] OlaparibAcute myeloid leukaemia: case report
Reactions Weekly, 2025, 2046 (1) : 333 - 333
[26] CapecitabineAcute myeloid leukaemia: case report
Reactions Weekly, 2007, 1163 (1) : 8 - 8
[27] AntineoplasticsAcute myeloid leukaemia: case report
Reactions Weekly, 2011, 1364 (1) : 7 - 7
[28] AzathioprineAcute myeloid leukaemia: case report
Reactions Weekly, 2023, 1972 (1) : 77 - 77
[29] AntineoplasticsAcute myeloid leukaemia: case report
Reactions Weekly, 2002, 885 (1) : 6 - 7
[30] AzathioprineAcute myeloid leukaemia: case report
Reactions Weekly, 2022, 1929 (1) : 123 - 123

← 1 2 3 4 5 →